PMID- 32527613
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 146
DP  - 2020 Aug
TI  - Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
PG  - 370-372
LID - S0169-5002(20)30401-3 [pii]
LID - 10.1016/j.lungcan.2020.04.031 [doi]
AB  - OBJECTIVES: Anaplastic lymphoma kinase (ALK) rearrangements account for 
      approximately 3-5% in non-small-cell lung cancer (NSCLC) patients who tend to be 
      young and never/light-smokers. Echinoderm microtubule-associated protein like 4 
      (EML4) is the most common partner for ALK fusion, while more than 90 other 
      partners have been reported in NSCLC. Majority of the ALK actionable 
      rearrangements were sensitive to crizotinib, yet some rare fusion types may less 
      benefit than EML4-ALK. Here, we reported a case of lung adenocarcinoma harboring 
      a novel S1 RNA binding domain 1 (SRBD1)-ALK fusion which the breakpoints was 
      (S6,A20). To our knowledge, this case is the first report showed clinical 
      evidence of SRBD1-ALK fusion responding to crizotinib. MATERIALS AND METHODS: 
      Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) examination 
      and next-generation sequencing (NGS) based on a 425-gene panel was performed on 
      the biopsy sample. RESULTS: The IHC analysis revealed positive expression of ALK 
      and atypical FISH signals were detected. Further NGS detected a novel SRBD1-ALK 
      fusion. The patient received crizotinib (250 mg, twice a day) as first-line 
      treatment and partial response was observed. The progression-free survival (PFS) 
      is already over than 10 months up to today. CONCLUSION: To our knowledge, our 
      case is the first case of SRBD1-ALK fusion with excellent response to crizotinib. 
      This case merits further follow-up and provides valuable information on the 
      response to crizotinib of NSCLC patients with SRBD1-ALK fusion.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Chen, Yao
AU  - Chen Y
AD  - Department of Medical Oncology, First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China.
FAU - Zhang, Xiaochen
AU  - Zhang X
AD  - Department of Medical Oncology, First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China.
FAU - Jiang, Qi
AU  - Jiang Q
AD  - Department of Medical Oncology, First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China.
FAU - Wang, Bo
AU  - Wang B
AD  - Department of Pathology, First Affiliated Hospital, College of Medicine, Zhejiang 
      University, Hangzhou, People's Republic of China.
FAU - Wang, Yina
AU  - Wang Y
AD  - Department of Medical Oncology, First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China. Electronic address: 
      1503099@zju.edu.cn.
FAU - Junrong, Yan
AU  - Junrong Y
AD  - Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
LA  - eng
PT  - Case Reports
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SRBD1 protein, human)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - *Adenocarcinoma of Lung/drug therapy/genetics
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - Crizotinib/therapeutic use
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Oncogene Proteins, Fusion/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - RNA-Binding Proteins
OTO - NOTNLM
OT  - NGS
OT  - NSCLC
OT  - SRBD1-ALK
OT  - crizotinib
COIS- Declaration of Competing Interest The authors report no conflicts of interest in 
      this work.
EDAT- 2020/06/13 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - S0169-5002(20)30401-3 [pii]
AID - 10.1016/j.lungcan.2020.04.031 [doi]
PST - ppublish
SO  - Lung Cancer. 2020 Aug;146:370-372. doi: 10.1016/j.lungcan.2020.04.031. Epub 2020 
      May 4.